Grossman E, Rosenthal T, Peleg E, Holmes C, Goldstein D S
Hypertension Unit, Chaim Sheba Medical Center, Tel-Hashomer, Israel.
J Cardiovasc Pharmacol. 1993 Jul;22(1):22-6. doi: 10.1097/00005344-199307000-00004.
Yohimbine is an alpha 2-adrenoceptor antagonist that is FDA approved for treatment of impotence. The drug is an indolalkylamine alkaloid chemically similar to reserpine and is believed to act through sympatholysis. We examined effects of oral yohimbine on blood pressure (BP) and plasma levels of catechols in patients with essential hypertension, a condition in which most drug treatments can produce impotence. In 25 unmedicated hypertensive subjects, vital signs were measured and blood samples were obtained through an indwelling antecubital venous catheter at baseline and 1 and 2 h after subjects ingested 4 5.4-mg tablets of yohimbine. Mean blood pressure (MBP) increased by an average of 5 mm Hg (p < 0.01), plasma norepinephrine (NE) levels increased by 66% (p < 0.001), and plasma dihydroxyphenylglycol (DHPG) levels increased by 25% (p < 0.01) at 1 h after drug administration. The magnitude of the pressor response was unrelated to baseline MBP but positively correlated with the baseline NE level (r = 0.61, p < 0.01) and with the yohimbine-induced increment in plasma NE (r = 0.4, p < 0.01). The results indicate that yohimbine does not inhibit and actually stimulates sympathetically mediated NE release in humans and that the increased NE release produces a pressor response. Yohimbine should be administered with caution to patients with high BP, especially in individuals with evidence for increased basal sympathetic outflow or those undergoing concurrent treatment with tricyclic antidepressants or other drugs that interfere with neuronal uptake or metabolism of NE.
育亨宾是一种α2 -肾上腺素能受体拮抗剂,已获美国食品药品监督管理局(FDA)批准用于治疗阳痿。该药物是一种吲哚烷基胺生物碱,化学结构与利血平相似,据信其作用机制是通过交感神经阻滞。我们研究了口服育亨宾对原发性高血压患者血压(BP)和儿茶酚血浆水平的影响,在原发性高血压这种疾病中,大多数药物治疗都可能导致阳痿。在25名未接受药物治疗的高血压受试者中,测量了生命体征,并在基线时以及受试者服用4片5.4毫克育亨宾片剂后1小时和2小时,通过留置的肘前静脉导管采集血样。给药后1小时,平均血压(MBP)平均升高5毫米汞柱(p < 0.01),血浆去甲肾上腺素(NE)水平升高66%(p < 0.001),血浆二羟苯乙二醇(DHPG)水平升高25%(p < 0.01)。升压反应的幅度与基线MBP无关,但与基线NE水平呈正相关(r = 0.61,p < 0.01),与育亨宾诱导的血浆NE增量呈正相关(r = 0.4,p < 0.01)。结果表明,育亨宾在人体中并不抑制实际上反而刺激交感神经介导的NE释放,并且NE释放增加会产生升压反应。对于高血压患者,尤其是那些有基础交感神经流出增加证据的个体,或正在同时接受三环类抗抑郁药或其他干扰NE神经元摄取或代谢的药物治疗的患者,应谨慎使用育亨宾。